Prytime Medical has announced the closing of a US$6 million inside financing round to support commercialisation of its resuscitative endovascular balloon occlusion of the aorta (REBOA) haemorrhage control products. “REBOA is different now,” said Andrew Holman, chief commercialisation officer at Prytime. “Our new Plus and Pro catheters include many new technical advancements that are enabling a surge […]
The post Prytime Medical closes US$6 million funding round to support commercialisation growth appeared first on Vascular News.